Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of real-world data
The combination of gemcitabine and cisplatin (gem/cis) with the anti-PD-L1-antibody durvalumab was recently approved as first line therapy for biliary tract cancer (BTC) based on the results of the TOPAZ-1 trial.
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 2024
|
| In: |
Targeted oncology
Year: 2024, Jahrgang: 19, Heft: 2, Pages: 213-221 |
| ISSN: | 1776-260X |
| DOI: | 10.1007/s11523-024-01044-1 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s11523-024-01044-1
|
| Verfasserangaben: | Alexander Olkus, Aurelie Tomczak, Anne Katrin Berger, Conrad Rauber, Philip Puchas, Cyrill Wehling, Thomas Longerich, Arianeb Mehrabi, De-Hua Chang, Jakob Liermann, Sophia Schäfer, Jan Pfeiffenberger, Dirk Jäger, Patrick Michl, Christoph Springfeld, Michael T. Dill |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1905252560 | ||
| 003 | DE-627 | ||
| 005 | 20241205180242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241009s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11523-024-01044-1 |2 doi | |
| 035 | |a (DE-627)1905252560 | ||
| 035 | |a (DE-599)KXP1905252560 | ||
| 035 | |a (OCoLC)1475314552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Olkus, Alexander |e VerfasserIn |0 (DE-588)1203731264 |0 (DE-627)1688771352 |4 aut | |
| 245 | 1 | 0 | |a Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer |b an exploratory analysis of real-world data |c Alexander Olkus, Aurelie Tomczak, Anne Katrin Berger, Conrad Rauber, Philip Puchas, Cyrill Wehling, Thomas Longerich, Arianeb Mehrabi, De-Hua Chang, Jakob Liermann, Sophia Schäfer, Jan Pfeiffenberger, Dirk Jäger, Patrick Michl, Christoph Springfeld, Michael T. Dill |
| 264 | 1 | |c March 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 28. Februar 2024 | ||
| 500 | |a Gesehen am 09.10.2024 | ||
| 520 | |a The combination of gemcitabine and cisplatin (gem/cis) with the anti-PD-L1-antibody durvalumab was recently approved as first line therapy for biliary tract cancer (BTC) based on the results of the TOPAZ-1 trial. | ||
| 700 | 1 | |a Tomczak, Aurelie |d 1982- |e VerfasserIn |0 (DE-588)1017513279 |0 (DE-627)690359810 |0 (DE-576)351218769 |4 aut | |
| 700 | 1 | |a Berger, Anne Katrin |d 1978- |e VerfasserIn |0 (DE-588)132177889 |0 (DE-627)519022424 |0 (DE-576)298988380 |4 aut | |
| 700 | 1 | |a Rauber, Conrad |d 1985- |e VerfasserIn |0 (DE-588)1068611642 |0 (DE-627)820522686 |0 (DE-576)427933900 |4 aut | |
| 700 | 1 | |a Puchas, Philip |e VerfasserIn |0 (DE-588)1344429378 |0 (DE-627)1905254342 |4 aut | |
| 700 | 1 | |a Wehling, Cyrill |d 1989- |e VerfasserIn |0 (DE-588)1136431187 |0 (DE-627)892909331 |0 (DE-576)490527817 |4 aut | |
| 700 | 1 | |a Longerich, Thomas |d 1974- |e VerfasserIn |0 (DE-588)128494514 |0 (DE-627)373916124 |0 (DE-576)297178059 |4 aut | |
| 700 | 1 | |a Mehrabi, Arianeb |d 1967- |e VerfasserIn |0 (DE-588)137664583 |0 (DE-627)594829763 |0 (DE-576)304831263 |4 aut | |
| 700 | 1 | |a Chang, De-Hua |d 1978- |e VerfasserIn |0 (DE-588)132043939 |0 (DE-627)517295210 |0 (DE-576)298911752 |4 aut | |
| 700 | 1 | |a Liermann, Jakob |d 1989- |e VerfasserIn |0 (DE-588)1147779287 |0 (DE-627)1007181842 |0 (DE-576)496034170 |4 aut | |
| 700 | 1 | |a Schäfer, Sophia |e VerfasserIn |0 (DE-588)1344432794 |0 (DE-627)1905255896 |4 aut | |
| 700 | 1 | |a Pfeiffenberger, Jan |d 1983- |e VerfasserIn |0 (DE-588)1019445386 |0 (DE-627)690902514 |0 (DE-576)358082498 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Michl, Patrick |d 1971- |e VerfasserIn |0 (DE-588)121336328 |0 (DE-627)081239203 |0 (DE-576)292654677 |4 aut | |
| 700 | 1 | |a Springfeld, Christoph |d 1972- |e VerfasserIn |0 (DE-588)123388910 |0 (DE-627)706281039 |0 (DE-576)293689385 |4 aut | |
| 700 | 1 | |a Dill, Michael T. |d 1983- |e VerfasserIn |0 (DE-588)1116508109 |0 (DE-627)871189305 |0 (DE-576)478447914 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Targeted oncology |d Paris : Springer Verlag France S.A.R.L., 2006 |g 19(2024), 2 vom: März, Seite 213-221 |h Online-Ressource |w (DE-627)507903838 |w (DE-600)2222136-0 |w (DE-576)284040207 |x 1776-260X |7 nnas |a Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer an exploratory analysis of real-world data |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:2 |g month:03 |g pages:213-221 |g extent:9 |a Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer an exploratory analysis of real-world data |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s11523-024-01044-1 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241009 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1116508109 |a Dill, Michael T. |m 1116508109:Dill, Michael T. |d 910000 |d 910100 |e 910000PD1116508109 |e 910100PD1116508109 |k 0/910000/ |k 1/910000/910100/ |p 16 |y j | ||
| 998 | |g 123388910 |a Springfeld, Christoph |m 123388910:Springfeld, Christoph |d 910000 |d 910100 |d 50000 |e 910000PS123388910 |e 910100PS123388910 |e 50000PS123388910 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 15 | ||
| 998 | |g 121336328 |a Michl, Patrick |m 121336328:Michl, Patrick |d 910000 |d 910100 |e 910000PM121336328 |e 910100PM121336328 |k 0/910000/ |k 1/910000/910100/ |p 14 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 13 | ||
| 998 | |g 1019445386 |a Pfeiffenberger, Jan |m 1019445386:Pfeiffenberger, Jan |d 910000 |d 910100 |e 910000PP1019445386 |e 910100PP1019445386 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 998 | |g 1147779287 |a Liermann, Jakob |m 1147779287:Liermann, Jakob |d 910000 |d 911400 |d 50000 |e 910000PL1147779287 |e 911400PL1147779287 |e 50000PL1147779287 |k 0/910000/ |k 1/910000/911400/ |k 0/50000/ |p 10 | ||
| 998 | |g 132043939 |a Chang, De-Hua |m 132043939:Chang, De-Hua |d 50000 |e 50000PC132043939 |k 0/50000/ |p 9 | ||
| 998 | |g 137664583 |a Mehrabi, Arianeb |m 137664583:Mehrabi, Arianeb |d 910000 |d 910200 |d 50000 |e 910000PM137664583 |e 910200PM137664583 |e 50000PM137664583 |k 0/910000/ |k 1/910000/910200/ |k 0/50000/ |p 8 | ||
| 998 | |g 128494514 |a Longerich, Thomas |m 128494514:Longerich, Thomas |d 910000 |d 912000 |e 910000PL128494514 |e 912000PL128494514 |k 0/910000/ |k 1/910000/912000/ |p 7 | ||
| 998 | |g 1136431187 |a Wehling, Cyrill |m 1136431187:Wehling, Cyrill |d 910000 |d 910100 |e 910000PW1136431187 |e 910100PW1136431187 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 1344429378 |a Puchas, Philip |m 1344429378:Puchas, Philip |d 910000 |d 910200 |e 910000PP1344429378 |e 910200PP1344429378 |k 0/910000/ |k 1/910000/910200/ |p 5 | ||
| 998 | |g 1068611642 |a Rauber, Conrad |m 1068611642:Rauber, Conrad |d 910000 |d 910100 |e 910000PR1068611642 |e 910100PR1068611642 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 132177889 |a Berger, Anne Katrin |m 132177889:Berger, Anne Katrin |d 910000 |d 910100 |d 50000 |e 910000PB132177889 |e 910100PB132177889 |e 50000PB132177889 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 3 | ||
| 998 | |g 1017513279 |a Tomczak, Aurelie |m 1017513279:Tomczak, Aurelie |d 910000 |d 912000 |e 910000PT1017513279 |e 912000PT1017513279 |k 0/910000/ |k 1/910000/912000/ |p 2 | ||
| 998 | |g 1203731264 |a Olkus, Alexander |m 1203731264:Olkus, Alexander |d 910000 |d 910100 |e 910000PO1203731264 |e 910100PO1203731264 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1905252560 |e 4589712105 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"given":"Alexander","role":"aut","display":"Olkus, Alexander","family":"Olkus"},{"family":"Tomczak","display":"Tomczak, Aurelie","role":"aut","given":"Aurelie"},{"role":"aut","given":"Anne Katrin","display":"Berger, Anne Katrin","family":"Berger"},{"display":"Rauber, Conrad","family":"Rauber","given":"Conrad","role":"aut"},{"display":"Puchas, Philip","family":"Puchas","given":"Philip","role":"aut"},{"family":"Wehling","display":"Wehling, Cyrill","given":"Cyrill","role":"aut"},{"display":"Longerich, Thomas","family":"Longerich","given":"Thomas","role":"aut"},{"given":"Arianeb","role":"aut","family":"Mehrabi","display":"Mehrabi, Arianeb"},{"role":"aut","given":"De-Hua","display":"Chang, De-Hua","family":"Chang"},{"family":"Liermann","display":"Liermann, Jakob","role":"aut","given":"Jakob"},{"role":"aut","given":"Sophia","display":"Schäfer, Sophia","family":"Schäfer"},{"family":"Pfeiffenberger","display":"Pfeiffenberger, Jan","given":"Jan","role":"aut"},{"given":"Dirk","role":"aut","display":"Jäger, Dirk","family":"Jäger"},{"display":"Michl, Patrick","family":"Michl","role":"aut","given":"Patrick"},{"display":"Springfeld, Christoph","family":"Springfeld","given":"Christoph","role":"aut"},{"given":"Michael T.","role":"aut","display":"Dill, Michael T.","family":"Dill"}],"id":{"doi":["10.1007/s11523-024-01044-1"],"eki":["1905252560"]},"name":{"displayForm":["Alexander Olkus, Aurelie Tomczak, Anne Katrin Berger, Conrad Rauber, Philip Puchas, Cyrill Wehling, Thomas Longerich, Arianeb Mehrabi, De-Hua Chang, Jakob Liermann, Sophia Schäfer, Jan Pfeiffenberger, Dirk Jäger, Patrick Michl, Christoph Springfeld, Michael T. Dill"]},"physDesc":[{"noteIll":"Illustrationen","extent":"9 S."}],"recId":"1905252560","relHost":[{"part":{"volume":"19","extent":"9","text":"19(2024), 2 vom: März, Seite 213-221","issue":"2","pages":"213-221","year":"2024"},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer an exploratory analysis of real-world dataTargeted oncology","note":["Gesehen am 08.11.2022"],"pubHistory":["1.2006 -"],"origin":[{"dateIssuedDisp":"2006-","dateIssuedKey":"2006","publisher":"Springer Verlag France S.A.R.L.","publisherPlace":"Paris"}],"title":[{"title_sort":"Targeted oncology","title":"Targeted oncology"}],"id":{"eki":["507903838"],"issn":["1776-260X"],"zdb":["2222136-0"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"507903838"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Online veröffentlicht: 28. Februar 2024","Gesehen am 09.10.2024"],"origin":[{"dateIssuedDisp":"March 2024","dateIssuedKey":"2024"}],"title":[{"title":"Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer","title_sort":"Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer","subtitle":"an exploratory analysis of real-world data"}]} | ||
| SRT | |a OLKUSALEXADURVALUMAB2024 | ||